ClinicalTrials.gg
CompletedNCT07812558Updated Sep 10, 2026

A Multicentre, Randomised, Double-blind, Positive-drug-controlled Phase III Clinical Trial on the Efficacy and Safety of CZ1S Peroneal Nerve Block Combined With Popliteal Artery and Posterior Capsule Gap Block for Postoperative Analgesia in Total Knee Arthroplasty.

A Phase 3 interventional study of ropivacaine (local infiltration) and CZ1S for Injection in Femoral Nerve Block (FNB), Interspace Between the Popliteal Artery and the Capsule of the Knee (IPACK) and Total Knee Arthroplasty (TKA), sponsored by Zhejiang Cuize Pharmaceutical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Zhejiang Cuize Pharmaceutical Technology Co., Ltd. · Phase 3, Interventional, and Supportive care

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Jul 2025, registered Sep 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a multicentre, randomised, double-blind, positive-drug-controlled confirmatory clinical trial designed to evaluate the efficacy and safety of CZ1S injection for femoral nerve block (FNB) combined with the interspace between the popliteal artery and the capsule of the knee (IPACK) block for postoperative analgesia following total knee arthroplasty (TKA).

02

Conditions studied

  • Femoral Nerve Block (FNB)
  • Interspace Between the Popliteal Artery and the Capsule of the Knee (IPACK)
  • Total Knee Arthroplasty (TKA)
03

In context

Lead sponsor

Zhejiang Cuize Pharmaceutical Technology Co., Ltd. is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  1. The subjects are able to understand the procedures and methods of this clinical trial (including pain intensity assessment methods), and voluntarily sign the form after being fully informed.
  2. Male or female aged 18-75 years; (BMI) within the range of [18.0-32.0] kg/m2 (including boundary values).
  3. Subjects scheduled for elective primary unilateral total knee arthroplasty under general anaesthesia.
  4. (ASA) classification I-III.
  5. Possess mobility and are able to walk 20 metres without assistance (only a four-legged walker may be used for balance).
  6. Normal pain and temperature sensation in the surgical limb.
  7. Female or male subjects of must agree to use effective from the time of signing the informed consent form until 30 days after administration of the medicinal product, for themselves and, in the case of male subjects, their partners.

Exclusion criteria: Subjects meeting any of the following criteria cannot be enrolled in this study:

  1. Subjects with pain unrelated to the indications for total knee arthroplasty, which the investigator judges may confound postoperative assessment (e.g., pain caused by lumbar nerve disease).
  2. Subjects planning to undergo surgery on other sites simultaneously.
  3. Subjects with a history of any of the following serious clinical diseases or currently suffering from serious diseases:

    1. Respiratory diseases: such as acute or bronchial asthma, pulmonary heart disease, other chronic lung diseases, or a history of respiratory depression;
    2. Circulatory system diseases: such as unstable angina and/or myocardial infarction within the past 6 months, patients with heart failure ( [NYHA] Class III-IV), atrial fibrillation, ventricular fibrillation, prolonged interval (12-lead examination): males ≥450ms, females ≥470ms (if initially abnormal, may retest three times and take the average); poorly controlled hypertension (resting seated systolic blood pressure ≥160mmHg for two or more consecutive readings, or diastolic blood pressure ≥100mmHg);
    3. Blood system diseases: bleeding disorders caused by clotting factor deficiencies or other coagulation abnormalities;
    4. Tumours: history of malignant tumour within the past year, except for non- basal cell carcinoma or squamous cell carcinoma of the skin or local cervical carcinoma in situ;
    5. Digestive system diseases: known gastrointestinal bleeding, gastrointestinal obstruction or perforation, or other diseases that may pose a risk to the gastrointestinal tract; f) Presence of other diseases that may significantly affect the evaluation of the investigational drug efficacy or metabolism in the body.
  4. Diagnosed progressive femoral nerve dysfunction or chronic neuromuscular injury.
  5. Subjects experiencing vomiting during the screening period or with a history of severe, postoperative nausea and vomiting.
  6. Subjects with screening laboratory results meeting the following criteria: a) Liver function: (ALT) or aspartate aminotransferase (AST) ≥2 times the (ULN) or total (TBIL) ≥1.5×ULN; b) Renal function: serum creatinine (Cr) ≥1.5×ULN; c) Coagulation function: (PT) >3s above the upper limit of normal and/or activated partial thromboplastin time (APTT) >10s above the upper limit of normal; d) Random blood glucose ≥11.1mmol/L.
  7. Individuals allergic to any component of the investigational medicinal product, general anaesthesia regimen drugs, rescue analgesics, or antiemetic medications, or with other .
  8. Use or anticipated use of opioids, NSAIDs, sedatives, anaesthetics, local anaesthetics, , antiepileptics, anxiolytics, antidepressants, traditional Chinese medicines with analgesic effects, class III antiarrhythmic drugs, potent CYP1A2 inhibitors, CYP1A2 highly sensitive substrates, potent inhibitors, CYP3A4 highly sensitive substrates, potent CYP3A4 inducers within five half-lives before randomisation (based on the actual drug label; if half-life is unknown, should be at least 48 hours), except as specified in the protocol. (See Appendix 1 for prohibited concomitant drugs/non-drug treatments)
  9. Regular alcohol consumption within the 3 months (90 days) prior to screening, defined as more than 14 units per week (1 unit = 360 mL of beer, or 45 mL of 40% spirit, or 150 mL of wine).
  10. Participation in a drug or device clinical trial within the 3 months (90 days) prior to screening, with use of investigational medicinal products or devices. Previous participation in clinical trials of this study drug or similar analgesics (including but not limited to Exparel ®, HYR-PB21, Aihengping®).
  11. History of drug abuse or substance abuse within 1 year prior to screening.
  12. Positive pregnancy test during the screening period, currently breastfeeding, or currently not breastfeeding but less than 6 months postpartum.
  13. Individuals deemed by the investigator to be unable to evaluate efficacy or unable to complete the trial.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
166 participants (actual)

Study arms

  • Active comparator
    Ropivacaine injection

    Ropivacaine injection

    Drug: ropivacaine (local infiltration)

  • Experimental
    CZ1S for injection

    CZ1S for injection

    Drug: CZ1S for Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Pain intensity is assessed using the Numerical Rating Scale (NRS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst pain imaginable. Higher scores indicate a worse outcome.

    Time frame: 72 hours

07

Study locations

1 site
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in Dec 2025, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2026
First posted
Sep 10, 2026
StartActual
Jul 3, 2025
Primary completionActual
Dec 30, 2025
CompletionActual
Dec 30, 2025
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07812558
Lead sponsor
Zhejiang Cuize Pharmaceutical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Sep 10, 2026
Start date
Jul 3, 2025
Primary completion
Dec 30, 2025
Completion
Dec 30, 2025
Last update
Sep 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion